Hidenobu Kojima

Hidenobu Kojima

Auto-generated profile, based on publicly available information

Hidenobu Kojima

Department of Surgery, Graduate School of Medicine Kyoto University Kyoto Japan

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 March 2020 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
KNKojiro Nakamura
Kojiro Nakamura
SKShoichi Kageyama
Shoichi Kageyama
FKFady M. Kaldas
Fady M. Kaldas
HHHirofumi Hirao
Hirofumi Hirao
TITakahiro Ito
Takahiro Ito
JKJerzy W. Kupiec-Weglinski
Jerzy W. Kupiec-Weglinski
Although CEACAM1 (CC1) glycoprotein resides at the interface of immune liver injury and metabolic homeostasis, its role in orthotopic liver transplantation (OLT) remains elusive. We aimed to determine whether/how CEACAM1 signaling may affect hepatic ischemia-reperfusion injury (IRI) and OLT outcomes. In the mouse, donor liver CC1 null mutation augmented IRI-OLT (CC1-KO→WT) by enhancing ROS expression and HMGB1 translocation during cold storage, data supported by in vitro studies where hepatic flush from CC1-deficient livers enhanced macrophage activation in bone marrow–derived macrophage cultures. Although hepatic CC1 deficiency augmented cold stress–triggered ASK1/p-p38 upregulation, adjunctive ASK1 inhibition alleviated IRI and improved OLT survival by suppressing p-p38 upregulation, ROS induction, and HMGB1 translocation (CC1-KO→WT), whereas ASK1 silencing (siRNA) promoted cytoprotection in cold-stressed and damage-prone CC1-deficient hepatocyte cultures. Consistent with mouse data, CEACAM1 expression in 60 human donor liver biopsies correlated negatively with activation of the ASK1/p-p38 axis, whereas low CC1 levels associated with increased ROS and HMGB1 translocation, enhanced innate and adaptive immune responses, and inferior early OLT function. Notably, reduced donor liver CEACAM1 expression was identified as one of the independent predictors for early allograft dysfunction (EAD) in human OLT patients. Thus, as a checkpoint regulator of IR stress and sterile inflammation, CEACAM1 may be considered as a denominator of donor hepatic tissue quality, and a target for therapeutic modulation in OLT recipients.

9 August 2023 in American Journal of Transplantation
Verified
Journal Article
Open access
ATAllyson Q. Terry
Allyson Q. Terry
HKHidenobu Kojima
Hidenobu Kojima
RSRebecca A. Sosa
Rebecca A. Sosa
FKFady M. Kaldas
Fady M. Kaldas
JCJackson L. Chin
Jackson L. Chin
ERElaine F. Reed
Elaine F. Reed
Ischemia-reperfusion injury (IRI) during orthotopic liver transplantation (OLT) contributes to graft rejection and poor clinical outcomes. The disulfide form of high mobility group box 1 (diS-HMGB1), an intracellular protein released during OLT-IRI, induces pro-inflammatory macrophages. How diS-HMGB1 differentiates human monocytes into macrophages capable of activating adaptive immunity remains unknown. We investigated if diS-HMGB1 binds toll-like receptor (TLR) 4 and TLR9 to differentiate monocytes into pro-inflammatory macrophages that activate adaptive immunity and promote graft injury and dysfunction. Assessment of 106 clinical liver tissue and longitudinal blood samples revealed that OLT recipients were more likely to experience IRI and graft dysfunction with increased diS-HMGB1 released during reperfusion. Increased diS-HMGB1 concentration also correlated with TLR4/TLR9 activation, polarization of monocytes into pro-inflammatory macrophages, and production of anti-donor antibodies. In vitro, healthy volunteer monocytes stimulated with purified diS-HMGB1 had increased inflammatory cytokine secretion, antigen presentation machinery, and reactive oxygen species production. TLR4 inhibition primarily impeded cytokine/chemokine and costimulatory molecule programs, whereas TLR9 inhibition decreased HLA-DR and reactive oxygen species production. diS-HMGB1-polarized macrophages also showed increased capacity to present antigens and activate T memory cells. In murine OLT, diS-HMGB1 treatment potentiated ischemia-reperfusion-mediated hepatocellular injury, accompanied by increased serum alanine transaminase levels. This translational study identifies the diS-HMGB1/TLR4/TLR9 axis as potential therapeutic targets in OLT-IRI recipients.

28 December 2024 in American Journal of Transplantation
Verified
Journal Article
Open access
HKHidenobu Kojima
Hidenobu Kojima
TMThomas A. Morinelli
Thomas A. Morinelli
YWYue Wang
Yue Wang
JCJackson L. Chin
Jackson L. Chin
AMAaron S. Meyer
Aaron S. Meyer
YZYuan Zhai
Yuan Zhai
As important immune regulatory cells, whether innate lymphoid cells (ILCs) are involved in liver transplantation (LT) remains unclear. In a murine orthotopic LT model, we dissected roles of ILCs in liver ischemia-reperfusion injury (IRI). Wild-type (WT) grafts suffered significantly higher IRI in Rag2-γc double knockout (DKO) than Rag2 knockout (KO) recipients, in association with downregulation of group 1 ILCs genes, including interferon gamma. Antibody-mediated ILC depletion or interferon gamma neutralization in Rag2 KO recipients increased, while interferon gamma treatment in DKO recipients reduced, liver graft injuries. At the donor side, grafts from DKO mice or anti-NK1.1-treated WT mice suffered significantly higher IRI, while grafts treated with interferon gamma during cold preservation decreased IRI. Thus, both recipient and donor group 1 ILCs protect liver grafts from IRI. Low-dose interferon gamma upregulated c-FLIP expression in vitro and in vivo and protected hepatocytes from inflammatory cell death. In human liver graft biopsies, single-cell RNA-sequencing analysis revealed group 1 ILCs produce interferon gamma. The c-FLIP levels were positively correlated with interferon gamma in pretransplant biopsies. Grafts with higher c-FLIP were associated with lower caspase-8 activation, IRI gradings, and frequency of early allograft dysfunction post-LT. Our study reveals a novel interferon gamma-mediated cytoprotective role of group 1 ILCs in LT.

8 March 2025 in American Journal of Transplantation
Verified
Journal Article
Open access
KTKosuke Tanaka
Kosuke Tanaka
YUYoichiro Uchida
Yoichiro Uchida
KKKentaro Kadono
Kentaro Kadono
SKShoichi Kageyama
Shoichi Kageyama
HKHiroshi Kawamoto
Hiroshi Kawamoto
EHEtsuro Hatano
Etsuro Hatano
Toll-like Receptor 4 (TLR4) plays a crucial role in ischemia/reperfusion injury (IRI) after liver transplantation (LT). However, the role of TLR4 in the context of steatotic grafts remains unclear. In this study, we developed a mouse model to explore IRI mechanisms in steatotic LT using TLR4 knockout mice as recipients. We successfully transplanted steatotic grafts with approximately 35% macrosteatosis and 5 hours of cold storage. Compared to normal LT, steatotic LT resulted in significantly higher serum level of alanine aminotransferase (ALT) and High Mobility Group Box 1 (HMGB1), higher transcriptional expression of inflammatory markers (C-X-C motif chemokine ligand 2, caspase-1, and caspase-11), and increased infiltration of CD11b-positive cells, correlating with lower survival. Serum HMGB1 and cleaved caspase-3 activation peaked earlier than serum ALT, with cold-stored steatotic grafts releasing more HMGB1. Notably, TLR4 knockout recipients demonstrated improved survival, attenuated inflammatory response, and reduced apoptosis. These findings suggest that TLR4 deficiency in recipients ameliorates IRI in steatotic LT, highlighting the importance of recipient immune modulation in mitigating steatotic graft injury.

25 February 2026 in Hepatology Research
Verified
Journal Article
Closed access
YHYusuke Hanabata
Yusuke Hanabata
TITakamichi Ishii
Takamichi Ishii
KMKenta Makino
Kenta Makino
TKTakuma Karasuyama
Takuma Karasuyama
KIKentaro Iwaki
Kentaro Iwaki
EHEtsuro Hatano
Etsuro Hatano

2 November 2026 in Journal of Hepato-Biliary-Pancreatic Sciences
Verified
Journal Article
Open access
KYKei Yamane
Kei Yamane
TITakashi Ito
Takashi Ito
TATakayuki Anazawa
Takayuki Anazawa
JFJunji Fujikura
Junji Fujikura
MOMakoto Okabe
Makoto Okabe
EHEtsuro Hatano
Etsuro Hatano
Pancreas–intestine composite transplantation (PITx) is a therapeutic option for patients with irreversible loss of both pancreatic and intestinal function. We report a case of PITx in a 16‐year‐old male who developed fulminant Type 1 diabetes mellitus complicated by non‐occlusive mesenteric ischemia, resulting in extensive intestinal necrosis. Despite intensive surgical and critical care management, the patient ultimately required total small intestinal resection and total pancreatectomy. After recovery from sepsis and multiorgan dysfunction, the patient's general condition stabilized, and PITx was considered an appropriate therapeutic option. The composite graft consisted of the pancreas, duodenum, small intestine, and right colon. Arterial inflow was reconstructed using a single Carrel patch incorporating the celiac axis and superior mesenteric artery, and venous outflow was established by portal vein anastomosis. Postoperatively, pancreatic endocrine function was restored, allowing stable glycemic control without exogenous insulin, and intestinal graft function enabled the gradual advancement of enteral and oral nutrition. This report highlights the key technical considerations and anatomical principles of PITx and demonstrates that tailored composite graft transplantation can restore both pancreatic and intestinal function while preserving unaffected abdominal organs in highly selected patients with combined pancreatic and intestinal failure.